Chengqi Zhizao Secures Tens of Millions in Angel Funding to Advance Membrane Filtration Instrument Innovation

VCBeat learned at the earliest opportunity that on October 10, 2024,Chengqi Zhizao (Beijing) Technology Co., Ltd. (hereinafter referred to as “Chengqi Zhizao”)Officially announced the completion of a tens-of-millions-yuan angel round of financing. This round of financing was led byHuatai GenScript, Tsinghua Innovation Ventures, Kinghand CapitalJoint Investment,Index CapitalServed as the exclusive financial advisor.

Chengqi Zhizao specializes in the development, manufacturing, sales, and service of membrane filtration instruments for the biopharmaceutical industry. Since its establishment, the company has achieved independent innovation and multiple iterations of self-optimization in product development, realizing product serialization (for laboratory-scale, pilot-scale, and large-scale production), commercialization, and customization to deeply meet customer and market demands. The company’s developedUnattended Fully Automated Tangential Flow Filtration System, filling a gap in both domestic and international markets and leading global technological innovation.

Chengqi Zhizao has always adhered to the belief that “Chengqi Zhizao · Becoming a Great Instrument,” crafting high-quality products, cultivating exceptional talent, and empowering users to become industry leaders. Demonstrating strength through quality and establishing market presence through service, the company’s products have been widely applied across various subfields of biopharmaceuticals, including antibodies, vaccines, nucleic acid drugs, cell therapy, and gene therapy. It has currently established partnerships withGenScript, WuXi Biologics, BeiGene, Chia Tai Tianqing, Innovent, SinopharmEstablished deep partnerships with dozens of leading clients in niche industries, achieved high-standard domestic substitution, and reached cooperation intentions with multiple overseas clients, resulting in rapid performance growth.

Huatai GenScriptIt was stated that in recent years, influenced by the international situation and geopolitics, supply chain issues in the life sciences industry and the laboratory equipment sector have become increasingly prominent, gradually emerging as one of the bottlenecks affecting the development of the biopharmaceutical industry. Ensuring a stable supply and achieving domestic production of life sciences products and laboratory equipment are key factors for guaranteeing the long-term development of biopharmaceutical enterprises, as well as an important prerequisite for the overall industrial upgrading of China’s biopharmaceutical sector—a trend aligned with broader market dynamics. The founding team of Chengqi Zhizao (Beijing) Technology Co., Ltd. possesses extensive entrepreneurial experience, with keen insight into industry pain points and needs. They can rapidly identify common challenges faced by customers and promptly provide solutions, developing a series of products that closely align with customer requirements. We are optimistic about the company’s future prospects and look forward to its ability to solve problems for more industry clients.

Sun Muyang, Investment Director at Tsinghua Innovation VenturesIt is stated that tangential flow filtration (TFF), as a critical step in the upstream processing of macromolecular drugs, remains dominated by imports due to process risks and customer-specific customization challenges, representing a niche blue-ocean market. Leveraging its efficient customer responsiveness and robust product R&D capabilities, Chengqi Zhizao (Beijing) Technology Co., Ltd. has established deep collaborations with numerous leading domestic clients within just one year of its product launch, rapidly achieving import substitution and significant revenue growth to become the top Chinese brand. As one of the few upstream supply chain companies in China that deeply integrates the “customer-centric” philosophy into both R&D and sales operations, we are optimistic about Chengqi Zhizao’s potential to evolve from TFF filters into an international leader in the macromolecular supply chain.

Zhang Dafeng, Chairman of KinghandCapitalWe highly value the Chengqi Zhizao team’s decade-plus of industry accumulation and their profound understanding of customer needs. By addressing key pain points in the tangential flow filtration sector, the company has demonstrated robust R&D and iterative capabilities in membrane filtration instrumentation, growing into an upstream biopharmaceutical enterprise with significant development potential. The team possesses acute market sensitivity and exceptional execution capabilities. We believe that under the leadership of its outstanding founding team, Chengqi Zhizao is poised to continuously expand its leading advantage, enrich its product portfolio, better serve downstream customers, and jointly advance the development of the biopharmaceutical industry, thereby benefiting more patients.

ChengMs. Jia Guiling, Founder & CEO of Chengqi ZhizaoFirst and foremost, I would like to express my gratitude to our team. The achievements Chengqi Zhizao has made today are inseparable from the collective efforts of every team member. Each of your creative ideas and dedicated contributions is deeply etched into the milestones of the company’s development. Secondly, I extend my thanks to our customers and partners. Your encouragement, recognition, and support have served as the driving force and guiding direction on our entrepreneurial journey, empowering us to continuously optimize and innovate. Special appreciation goes to our investors. In the current “capital winter,” your decision to invest in Chengqi Zhizao represents not only immense trust and support but also a profound sense of responsibility and expectation. We are committed to persevering and living up to your confidence. Finally, I would like to thank Index Capital, the financial advisor for this financing round, and Zhong Lun Law Firm, the legal advisor. Thank you for your high level of professionalism and dedication in supporting this financing effort. This round of financing provides us with more abundant resources to expand our business footprint, accelerate technological R&D, and deepen our market presence. It will undoubtedly propel Chengqi Zhizao to become a leading enterprise in the field of membrane filtration instruments for biopharmaceuticals. We will remain courageous, resilient, and steadfast, continuously shaping our core corporate values, contributing to life and health, and dedicating our strength to the development of the global life sciences industry.